This is an international site for Tasigna® (Nilotinib) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.

I am a healthcare professional outside the U.S. I am a U.S. resident I am a patient outside the U.S.
Print Text Size Glossary Summary of Product Characteristics Safety Information U.S. Residents

This site is intended for Healthcare Professionals outside the U.S.

Patient FAQ
Tips For Taking TASIGNA
Interactive Dosing Questionnaire

INTERACTIVE DOSING QUESTIONNAIRE

What’s your TASIGNA time?

You probably already have a suitable window in your daily routine that is a good time to take your TASIGNA dose. Answering these questions takes less than 3 minutes and can help you find the best time to take your TASIGNA.

Think of your usual everyday schedule:

1. What time do you get up?
Please enter a valid time (e.g. 7:30). Please fill out the form completely.
 :
2. What time do you go to bed?
Please enter a valid time (e.g. 7:30). Please fill out the form completely.
 :
3. When do you like to eat breakfast?
Please enter a valid time (e.g. 7:30). Please fill out the form completely.
 :
4. When do you like to eat dinner?
Please enter a valid time (e.g. 7:30). Please fill out the form completely.		 :

Do you agree or disagree with the following statements?

1. I need to eat breakfast as soon as I get up (<1 hour) Agree Disagree
2. It’s important to me to eat dinner with my family Agree Disagree
3. I like to snack or eat supper right before bed Agree Disagree
4. I wake and eat early during the week, but sometimes I like to sleep later or go out for breakfast on weekends Agree Disagree

This tool will generate your results as a PDF. If you are having trouble viewing your results,
please download Adobe® Reader®.


References:
1. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of Bcr-Abl for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer. 2007;7(5):345-356.
2. TASIGNA® (nilotinib) Summary of Product Characteristics. Basel, Switzerland: Novartis Pharma AG; June 2011.

TASIGNA Interactive Game

To see how TASIGNA is an optimized Bcr-Abl inhibitor that was designed to improve on imatinib, visit TASIGNA mechanism of action.1

Learn how the favorable tolerability profile may help patients adhere to therapy.2